ICD-10-CM Billable Code

C95.9

Leukemia, unspecified

Clinical Classification Guidelines

Medical Intelligence & Overview

Leukemia, unspecified (ICD-10 code C95.9), is a type of blood cancer characterized by an uncontrolled growth of abnormal white blood cells. These abnormal cells interfere with the body's ability to fight infections, carry oxygen, and control bleeding. Because the exact type of leukemia isn't specified, diagnosis and treatment often involve additional testing to determine the specific form. Symptoms can develop gradually and may be similar to other illnesses, making medical evaluation essential for accurate diagnosis and management.

Causes & Symptoms

Clinical Causes: Genetic mutations that affect blood cell production Inherited genetic conditions Previous exposure to radiation or chemotherapy Exposure to certain chemicals or environmental toxins Family history of blood cancers Weakened immune system

Key Symptoms: Feeling tired or weak Frequent infections or fever Unexplained weight loss Swollen lymph nodes, spleen, or liver Easy bruising or bleeding Night sweats Bone or joint pain Pale skin due to anemia Shortness of breath

Diagnostic & Treatment

Diagnosis Path: The diagnosis of leukemia, unspecified involves a combination of tests, including blood tests to evaluate blood cell counts, and bone marrow biopsy to assess abnormal cell presence. Additional tests, such as cytogenetic analysis and imaging studies, may be necessary to exclude other conditions and determine the extent of the disease. Since the leukemia is unspecified, further testing helps specify the type for targeted treatment planning.

Treatment Protocols: Treatment options for leukemia, unspecified, typically depend on the patient's overall health and the specific characteristics of the leukemia. Common approaches include chemotherapy to destroy abnormal cells, targeted therapy to attack specific genetic mutations, radiation therapy, and sometimes stem cell or bone marrow transplantation. Supportive care, such as blood transfusions and antibiotics, also plays a crucial role in managing symptoms and preventing complications. Ongoing monitoring and follow-up are essential for assessing treatment response and adjusting therapies as needed.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is C95.9 a billable ICD-10 code?
Yes, C95.9 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report C95.9?
Clinical documentation must specify the nature of Leukemia, unspecified and any associated comorbidities for accurate reporting.

Cite this Clinical Reference